Healthcare has spent decades treating people according to averages: the average patient, the average disease progression and the average response to a drug. But biology does not work in averages.
The cost and speed of DNA sequencing have fallen dramatically, making genomic information increasingly practical for clinical use. At the same time, biomarkers and wearable devices are creating a much more continuous picture of how an individual’s health changes.
The bigger opportunity is what happens when these streams come together. Genomics can indicate what someone may be predisposed to; biomarkers can show what is happening now; continuous tracking can reveal how the body responds over time.
That changes the purpose of personalized medicine. It is not simply about finding a more sophisticated diagnosis after someone becomes sick. It is about building enough individual context to identify meaningful risk earlier and make treatment more precise.
The real shift, therefore, is from treating the average patient to understanding the individual patient.
The 4D Health Stack
The real power of personalized medicine will not come from one DNA test. It will come from stacking four layers of information.
- Static Baseline- Genomics: DNA provides the inherited blueprint: what a person may be predisposed to.
- Dynamic Reality- Biomarkers: Measures such as ApoB, hs-CRP and blood glucose show what is happening biologically now.
- Continuous Context- Wearables: Heart rate, sleep, activity and continuous glucose data can reveal how the body responds to everyday behaviour over time.
- Clinical Decision Engine- AI + Physician: The final layer turns these signals into something useful: a doctor can combine the data with medical history and decide what actually warrants intervention.
This framework matters because more data is not the same as better medicine. The value comes from connecting different types of information. A genetic predisposition might look concerning in isolation but become far more or less relevant when viewed alongside current biomarkers and long-term trends.
The future of personalized medicine, therefore, is not a bigger genetic report. It is a connected health profile that turns biological complexity into a clinical decision.
When Your Genes Change The Prescription
Personalized medicine becomes much more tangible when it reaches the prescription pad. Pharmacogenomics can show that two patients taking the same drug may process it differently because of genetic variation.
Take CYP2C19 and clopidogrel, an antiplatelet drug used to reduce the risk of cardiovascular events. CYP2C19 helps convert clopidogrel into its active form. People with reduced-function variants can produce less active drug, potentially reducing platelet inhibition and increasing cardiovascular risk. CPIC guidelines therefore use CYP2C19 genotype to help guide antiplatelet therapy in relevant patients.
The same principle applies to CYP2D6 and CYP2C19 for several commonly used antidepressants. Genetic differences can influence how these medicines are metabolized, affecting their potential efficacy, tolerability and dosing considerations.
This is where personalized medicine becomes genuinely practical. The question is no longer simply which drug treats the disease, but which drug is more likely to work for this particular patient.
That could reduce some of the trial-and-error built into prescribing but only where the genetic evidence is strong enough to support a clinical decision.
From Single Genes To Thousands Of Genetic Signals
Most major diseases are not controlled by one gene. Conditions such as coronary artery disease and Type 2 diabetes are influenced by hundreds or thousands of genetic variants, each contributing a small amount to overall risk.
This is where polygenic risk scores (PRS) become interesting. Instead of looking for one “disease gene,” a PRS combines the effects of many genetic variants to estimate an individual’s inherited susceptibility to a complex condition.
The potential is significant. Someone may have a high inherited risk for coronary artery disease despite having no symptoms today. That information could potentially support earlier screening or more focused prevention, particularly when combined with conventional factors such as cholesterol, blood pressure and family history.
But PRS should not be treated as a prediction of destiny. Its usefulness can vary across populations because many genetic studies have historically relied heavily on people of European ancestry. A score that performs well in one population may not perform equally well in another.
That limitation matters. Personalized medicine cannot truly be personalized if the underlying data does not represent the people it is being used on.
The opportunity is therefore substantial but so is the responsibility to make genomic prediction clinically validated, diverse and actionable.
The Prevention Paradox: Who Pays For A Healthier Future?
Personalized medicine could make prevention more valuable, but healthcare economics may not always reward it.
Suppose a genomic test identifies elevated cardiovascular risk today and leads to years of earlier monitoring and intervention. The savings from avoiding a major cardiovascular event may occur far into the future. Yet the insurer paying for the test today may not be the same insurer covering that patient years later.
This creates a reimbursement paradox: the organisation funding prevention bears the immediate cost, while another payer or the healthcare system as a whole may capture much of the future benefit.
The problem becomes even harder when the value of a test is measured against conventional healthcare budgets. A genomic panel can produce useful information without immediately producing a billable treatment. That makes it harder to fit into a healthcare model historically built around diagnosing and treating existing disease.
I see this as one of the biggest barriers to personalized medicine at scale. The technology may become affordable before the economics catch up.
For genomic prevention to move beyond premium healthcare, insurers and health systems will need to evaluate long-term avoided costs and improved outcomes, not simply whether a test creates an immediate medical intervention.
Otherwise, healthcare could remain financially structured to reward treating disease rather than preventing it.
The N-of-1 Trial: When the Patient Becomes the Experiment
Personalized medicine could eventually change more than treatment, it could change how we generate evidence.
Traditional clinical trials are designed to discover what works for large populations. That is essential for proving whether a treatment is safe and effective, but it inevitably produces averages. Personalized medicine introduces another possibility: the N-of-1 trial, where an individual’s response to an intervention is tracked systematically over time.
Imagine a patient with a particular genetic profile, metabolic pattern and set of biomarkers. Instead of relying only on population averages, clinicians could track how that specific patient responds to a dietary intervention, medication or other clinically appropriate change, using repeated measurements to assess the outcome.
This does not replace large clinical trials. Population-level evidence remains the foundation of safe medicine. But N-of-1 approaches could add another layer of evidence: what works for this patient, under these conditions?
That is a profound shift. Medicine has historically asked, “Does this treatment work on average?” Personalized healthcare increasingly asks a second question: “How does this individual respond?”
The future may therefore combine both forms of evidence, large trials to establish what generally works and individual-level data to refine what works best for a particular patient.
The Downside Of Too Much Information
The biggest mistake in personalized medicine would be assuming that every new piece of biological information is useful.
Broad genetic testing can uncover variants of uncertain significance (VUS)– genetic changes whose connection to disease is not yet established. Finding one does not automatically mean that a person has, or will develop, a particular condition. Yet without careful interpretation, uncertain findings can trigger anxiety, unnecessary follow-up testing and sometimes invasive procedures.
This creates what I call the incidentaloma problem of genomics: the ability to detect more abnormalities faster than medicine can confidently explain them.
The same issue can appear outside genetics. More sensitive biomarker testing can identify small biological deviations that may never develop into clinically meaningful disease. If every abnormal result leads to another test, healthcare risks creating a cycle of overdiagnosis rather than prevention.
This is why precision medicine needs a strict principle: information should only be collected when there is a credible pathway from finding it to acting on it.
The goal should not be to know everything about a patient. It should be to know what matters enough to change the outcome.
The People Problem
Personalized medicine has a technology problem, but it also has a talent problem.
A genomic report can contain thousands of variants, but identifying which ones actually matter requires specialised interpretation. Genetic counsellors, clinical geneticists and physicians trained in genomic medicine are needed to translate complex findings into decisions patients can understand and act on.
The challenge becomes even greater as healthcare moves toward multi-omics– combining genomics with biomarkers, proteomics, metabolomics and continuous health data. More information can improve precision, but it also increases the complexity of interpretation.
AI could help by identifying patterns and reducing the burden of analysing huge datasets. But I do not see AI replacing clinical judgment here. The more complicated the data becomes, the more important human interpretation becomes.
This creates a bottleneck that is easy to overlook. Sequencing can scale much faster than expertise.
Unless healthcare systems invest in the people, training and clinical infrastructure needed to interpret genomic data, personalized medicine risks becoming a technology that can generate remarkable insights but cannot consistently turn those insights into better patient outcomes.
Conclusion
The biggest mistake would be judging personalized medicine by how much data it can collect. The real test is whether that data leads to better decisions and better outcomes.
Genomics can reveal inherited risk. Biomarkers can show what is changing inside the body. Wearables can add continuous context. AI can help connect these signals. But none of this matters if the information is inaccurate, inaccessible, poorly interpreted or impossible to act on.
That is why I see the next phase of personalized medicine less as a race to collect more data and more as a race to make biological information clinically useful.
The strongest healthcare model will not be the one that predicts the most diseases. It will be the one that knows which risks are meaningful, which interventions are supported by evidence and when doing nothing is actually better than intervening.
If genomic testing becomes affordable, clinical interpretation improves and healthcare systems start rewarding prevention, personalized medicine could fundamentally change the patient journey.
The future of healthcare is not simply knowing more about each person. It is knowing which information matters and acting on it at the right time.
